Simulations Plus (NASDAQ:SLP) Issues Earnings Results

Simulations Plus (NASDAQ:SLP) issued its quarterly earnings data on Wednesday. The technology company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02, Briefing.com reports. Simulations Plus had a net margin of 14.36% and a return on equity of 7.80%. The business had revenue of $18.70 million during the quarter, compared to the consensus estimate of $19.73 million. During the same period in the prior year, the firm posted $0.18 EPS. The firm’s quarterly revenue was up 19.9% compared to the same quarter last year. Simulations Plus updated its FY25 guidance to $1.07 to $1.20 EPS and its FY 2025 guidance to 1.070-1.200 EPS.

Simulations Plus Stock Performance

NASDAQ SLP traded down $0.94 during trading on Friday, hitting $30.02. 149,572 shares of the company’s stock traded hands, compared to its average volume of 129,462. The stock has a market capitalization of $600.70 million, a price-to-earnings ratio of 64.50 and a beta of 0.69. Simulations Plus has a 12-month low of $29.37 and a 12-month high of $51.22. The business has a 50 day moving average of $33.20 and a 200-day moving average of $40.76.

Insider Activity

In related news, Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $35.18, for a total value of $703,600.00. Following the completion of the transaction, the director now directly owns 3,501,592 shares of the company’s stock, valued at approximately $123,186,006.56. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 60,750 shares of company stock valued at $2,145,055 over the last quarter. Company insiders own 20.90% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on SLP. Craig Hallum reaffirmed a “buy” rating and set a $56.00 price target on shares of Simulations Plus in a research report on Wednesday, July 3rd. JMP Securities assumed coverage on Simulations Plus in a research note on Tuesday, July 16th. They set a “market perform” rating on the stock. William Blair restated an “outperform” rating on shares of Simulations Plus in a research report on Thursday. BTIG Research lowered their price objective on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, KeyCorp assumed coverage on shares of Simulations Plus in a research note on Monday, July 29th. They issued an “overweight” rating and a $47.00 target price on the stock. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $54.50.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.